- Home
- MIRM vs AKRO Comparison
MIRM vs AKRO Comparison
Compare MIRM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- AKRO
- Stock Information
- Founded
- MIRM 2018
- AKRO 2017
- Country
- MIRM United States
- AKRO United States
- Employees
- MIRM 349
- AKRO N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MIRM Health Care
- AKRO Health Care
- Exchange
- MIRM Nasdaq
- AKRO Nasdaq
- Market Cap
- MIRM 3.7B
- AKRO 3.7B
- IPO Year
- MIRM 2019
- AKRO 2019
- Fundamental
- Price
- MIRM $72.85
- AKRO $46.50
- Analyst Decision
- MIRM Strong Buy
- AKRO Strong Buy
- Analyst Count
- MIRM 11
- AKRO 8
- Target Price
- MIRM $76.09
- AKRO $80.38
- AVG Volume (30 Days)
- MIRM 712.9K
- AKRO 1.2M
- Earning Date
- MIRM 11-11-2025
- AKRO 11-07-2025
- Dividend Yield
- MIRM N/A
- AKRO N/A
- EPS Growth
- MIRM N/A
- AKRO N/A
- EPS
- MIRM N/A
- AKRO N/A
- Revenue
- MIRM $429,161,000.00
- AKRO N/A
- Revenue This Year
- MIRM $53.14
- AKRO N/A
- Revenue Next Year
- MIRM $19.83
- AKRO N/A
- P/E Ratio
- MIRM N/A
- AKRO N/A
- Revenue Growth
- MIRM 62.33
- AKRO N/A
- 52 Week Low
- MIRM $36.88
- AKRO $21.34
- 52 Week High
- MIRM $78.10
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- MIRM 56.46
- AKRO 47.87
- Support Level
- MIRM $70.49
- AKRO $45.20
- Resistance Level
- MIRM $74.96
- AKRO $47.40
- Average True Range (ATR)
- MIRM 1.82
- AKRO 1.46
- MACD
- MIRM -0.72
- AKRO 0.06
- Stochastic Oscillator
- MIRM 51.03
- AKRO 34.90
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.